GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] proposal — a flair for dual agonist posts — 15 comments in the full submission. View in context.
253
c/survodutide·submitted 18 days ago by u/renzo_yildiz

[Meta] proposal — a flair for dual agonist posts

Paperbranch of 7 comments

Housekeeping: proposal — a flair for dual agonist posts. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use. Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost…

Read the full submission and all 15 comments →

This branch

7 comments, started 17 days ago
u/incretin_ivyMOD23 points·17 days ago

Independent result logged. There are almost none for this compound, so it is genuinely valuable.

replysharereportpermalink
u/heart_rate_bump18 points·17 days ago

Which phase and which arm are you quoting?

replysharereportpermalink
u/patient_labslip_log14 points·17 days ago

Which phase and which arm are you quoting?

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/hugo_bergstrom3 points·17 days ago

What does the tolerability table say at that dose?

replysharereportpermalink
u/renzo_yildizOP2 points·17 days ago

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

replysharereportpermalink
u/cold_chromatogram_only2 points·17 days ago

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

replysharereportpermalink
u/renzo_yildiz9 points·17 days ago

Biopsy-confirmed population or imaging-selected?

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →